- Home
- IPW vs ELEV Comparison
IPW vs ELEV Comparison
Compare IPW & ELEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPW
- ELEV
- Stock Information
- Founded
- IPW 2018
- ELEV 2019
- Country
- IPW United States
- ELEV United States
- Employees
- IPW N/A
- ELEV N/A
- Industry
- IPW Catalog/Specialty Distribution
- ELEV Biotechnology: Pharmaceutical Preparations
- Sector
- IPW Consumer Discretionary
- ELEV Health Care
- Exchange
- IPW Nasdaq
- ELEV Nasdaq
- Market Cap
- IPW 14.4M
- ELEV 22.6M
- IPO Year
- IPW 2021
- ELEV 2021
- Fundamental
- Price
- IPW $0.70
- ELEV $0.38
- Analyst Decision
- IPW
- ELEV Hold
- Analyst Count
- IPW 0
- ELEV 6
- Target Price
- IPW N/A
- ELEV $1.77
- AVG Volume (30 Days)
- IPW 298.7K
- ELEV 938.5K
- Earning Date
- IPW 05-15-2025
- ELEV 08-05-2025
- Dividend Yield
- IPW N/A
- ELEV N/A
- EPS Growth
- IPW N/A
- ELEV N/A
- EPS
- IPW N/A
- ELEV N/A
- Revenue
- IPW $74,105,251.00
- ELEV N/A
- Revenue This Year
- IPW $8.31
- ELEV N/A
- Revenue Next Year
- IPW $77.15
- ELEV N/A
- P/E Ratio
- IPW N/A
- ELEV N/A
- Revenue Growth
- IPW N/A
- ELEV N/A
- 52 Week Low
- IPW $0.41
- ELEV $0.22
- 52 Week High
- IPW $2.36
- ELEV $3.28
- Technical
- Relative Strength Index (RSI)
- IPW 58.09
- ELEV 54.73
- Support Level
- IPW $0.67
- ELEV $0.36
- Resistance Level
- IPW $0.73
- ELEV $0.38
- Average True Range (ATR)
- IPW 0.06
- ELEV 0.01
- MACD
- IPW 0.00
- ELEV -0.00
- Stochastic Oscillator
- IPW 55.92
- ELEV 53.93
About IPW iPower Inc.
iPower Inc is online hydroponic equipment and accessory retailer and supplier in North America. The company sells products through own website as well as online channel partners that include Amazon, Walmart, and eBay.
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.